Photo: Kestra Medical Technologies, BioBeat Technologies
Jan. 13, 2026 — Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced a strategic collaboration with Biobeat Technologies, Ltd. to expand diagnostic insight for patients prescribed the Assure Wearable Cardioverter Defibrillator (WCD). The agreement is anchored by an exclusive license and co-development arrangement and includes a $5 million equity investment in Biobeat’s recently announced Series B financing.
Biobeat has developed the only clinically validated, FDA-cleared cuffless, patch-worn ambulatory blood pressure monitoring (ABPM) device, leveraging photoplethysmography-based sensing to deliver continuous, noninvasive blood pressure measurement over a 24-hour period for hypertension diagnosis and management in the outpatient cardiac recovery setting. Kestra intends to integrate Biobeat’s technology into its product portfolio to make ABPM data available for patients prescribed the ASSURE WCD.
Kestra recently published the largest prospective real-world study of wearable defibrillators to date and insights from Assure Wearable Cardioverter Defibrillator Clinical Evaluation Post-Approval Study (ACE-PAS) underscore the clinical relevance of the collaboration with Biobeat. Seventy-two percent (72%) of the patients studied in ACE-PAS were hypertensive, highlighting the complexity of managing blood pressure during cardiac recovery, particularly during guideline-directed medical therapy (GDMT) optimization.
“Health care providers have consistently told us that better visibility to blood pressures during cardiac recovery would meaningfully support clinical decision making,” said Brian Webster, President and CEO of Kestra. “This collaboration allows us to expand the clinical insights available during recovery while reinforcing ASSURE as a flexible platform designed to support at-home patient care.”
Arik Ben Ishay, CEO of Biobeat, added, “Kestra has built a scalable platform focused on protecting and supporting patients during cardiac recovery. We are excited to collaborate with Kestra as they explore how our FDA-cleared, 24-hour blood pressure monitoring for hypertension diagnosis may complement their Cardiac Recovery System® platform and expand the clinical insights available to care teams managing complex cardiac patients.”
For more information, please visit www.kestramedical.com and www.bio-beat.com.
January 13, 2026 
